Drugs / COVIGENIX VAX- 002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06436911 | Jul 2024 → Oct 2025 | COVID-19 | Entos Pharmaceuticals Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-07-08 | Entos Pharmaceuticals Inc. | Regulatory Entos Receives Health Canada Approval to Start Clinical Trial entospharma.com ↗
today announced that Entos has received approval from Health Canada to initiate a phase 1/2 clinical trial (NCT06436911) evaluating Covigenix VAX-002, an investigational COVID-19 booster vaccine. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-07-08 | Entos Pharmaceuticals Inc. | Entos Receives Health Canada Approval to Start Clinical Trial entospharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVIGENIX VAX- 002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06436911 ↗ |
| Known as | VAX-002 | “Covigenix VAX-002 is a vaccine based off its predecessors VAX-001 and VAX-001-1b.” NCT06436911 ↗ |
| Modality | Vaccine | “All three are plasmid DNA vaccines” NCT06436911 ↗ |